Abbvie hopes to turn around the fortunes of Sting
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
Asco 2019 – Seattle sees an Adcetris follow-up on the horizon at last
A mid-stage study of enfortumab illustrates the relevance of nectin-4 in urothelial bladder cancer, and is hailed by experts as registrational.
Upcoming events – cancer readouts for Merck & Co and Seattle
Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.
